399 Binney Street
2nd Floor
Cambridge, MA 02139
United States
617 370 8837
https://www.relaytx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 309
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Alexis A. Borisy A.M. | Co-Founder & Independent Chairman | 92.5k | N/D | 1972 |
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | CEO, President & Director | 1.08M | 1.96M | 1974 |
Dr. Mark Murcko Ph.D. | Co-Founder & Director | 60k | N/D | 1960 |
Mr. Thomas Catinazzo | Chief Financial Officer | 663.99k | N/D | 1977 |
Mr. Brian R. Adams J.D. | Chief Legal Officer & Secretary | 627.72k | N/D | 1974 |
Mr. Peter Rahmer | Chief Corporate Development Officer | 626.62k | N/D | N/D |
Dr. Donald A. Bergstrom M.D., Ph.D. | President of Research & Development | 1.37M | N/D | 1972 |
Mr. Jim Watters Ph.D. | Chief Scientific Officer of Late Research | N/D | N/D | N/D |
Dr. Beni B. Wolf M.D., Ph.D. | Chief Medical Officer & Head of Precision Medicine | N/D | N/D | N/D |
Dr. Mahesh Padval Ph.D. | Chief Pharmaceutical Development Officer | N/D | N/D | N/D |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
La calificación ISS Governance QuickScore de Relay Therapeutics, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 6; Junta: 7; Derechos del accionista: 8; Compensación: 8.